Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Coherus BioSciences, Inc. (CHRS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/06/2023 |
8-K
| Unregistered Sales of Equity Securities Interactive Data |
| 08/02/2023 |
8-K
| Quarterly results |
| 07/20/2023 |
8-K
| Quarterly results |
| 06/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte... |
| 06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/31/2023 |
8-K
| Other Events Interactive Data |
| 05/18/2023 |
8-K
| Asset disposition |
| 05/15/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 05/08/2023 |
8-K
| Quarterly results |
| 03/06/2023 |
8-K
| Quarterly results |
| 11/08/2022 |
8-K
| Quarterly results |
| 09/15/2022 |
8-K
| Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ... |
| 09/09/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/04/2022 |
8-K
| Quarterly results |
| 05/20/2022 |
8-K
| Quarterly results |
| 05/13/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
8-K
| Quarterly results |
| 04/01/2022 |
8-K
| Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ... |
| 02/17/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/07/2022 |
8-K
| Quarterly results |
| 01/13/2022 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"FORM 8-K",
"Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody • Coherus and Junshi Biosciences plan to evaluate the toripalimab + JS006 combination in clinical trials in multiple tumor types • Combinations of PD-1 + TIGIT inhibitors have potential to expand checkpoint inhibitor utilization to new tumors and lines of therapy REDWOOD CITY, Calif., and SHANGHAI, China, Jan. 10, 2022 — Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. today announced that Coherus has initiated the process to exercise its option to license JS006, Junshi Biosciences' TIGIT-targeted antibody, in the United States and Canada, expanding the companies' 2021 immuno-oncology collaboration agreement. Coherus will pay Junshi Biosciences $35 million upfront, up t..." |
|
| 01/07/2022 |
8-K
| Credit agreement amendment |
| 12/03/2021 |
8-K
| Quarterly results |
| 11/08/2021 |
8-K
| Quarterly results |
| 10/13/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Coherus BioSciences Mourns the Passing of Board Member Alan C. Mendelson REDWOOD CITY, Calif., Oct. 11, 2021 — It is with profound sadness that Coherus BioSciences, Inc. announces the unexpected passing of board member Alan C. Mendelson. He had been a director of the Company since January 2021 and had previously served as external legal counsel since its founding in 2010. “Alan was truly a titan of the biotech industry, without peer in his discipline, and this is such tremendous loss on so many levels for so many people,” said Denny Lanfear, CEO of Coherus. “His contributions and impact on the industry through its genesis and evolution are difficult to overstate. I am honored to have had him as a decades-long personal friend, inspiring mentor, and the most trusted of advisors.” Mr. Lanfear..." |
|
| 09/29/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Coherus BioSciences Mourns the Passing of Board Member Dr. Samuel Nussbaum REDWOOD CITY, Calif., Sept. 29, 2021 — It is with profound sadness that Coherus BioSciences, Inc. announces the passing of board member Samuel Nussbaum, M.D. During his distinguished career, Dr. Nussbaum worked as a physician, researcher, professor, and healthcare executive. He had been a director of the Company since May 2018. “We will greatly miss Sam and his tremendous support for Coherus. Long before joining the Coherus board, he lived a mission of providing greater access to life-changing medicines,” said Denny Lanfear, CEO of Coherus. “We were privileged to benefit from his guidance and counsel during his time on our Board, and I will forever be grateful for his service. The entire Coherus team offers our cond..." |
|
| 08/11/2021 |
8-K
| Quarterly results |
| 08/05/2021 |
8-K
| Quarterly results |
| 05/26/2021 |
8-K
| Quarterly results |
| 05/06/2021 |
8-K
| Quarterly results |
| 02/24/2021 |
8-K
| Quarterly results |
| 02/12/2021 |
8-K
| Quarterly results |
| 02/02/2021 |
8-K
| Quarterly results |
|
|
|